Emerging Views On Emerging Markets: JP Morgan Healthcare Conference (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Emerging markets continued to play a large role in company presentations during the industry’s largest investor conference. In this feature, PharmAsia News takes a closer look.
You may also be interested in...
In India, Sanofi CEO Christopher Viehbacher Speaks On R&D, Pricing Policies And M&A Deals (Part 1 of 2)
Sanofi Global CEO Christopher Viehbacher says he is a great fan of India. With a large market unfolding, Viehbacher knows his priorities. He projects that as much as 40% of Sanofi's sales in the next five years will come from emerging markets like India.
Pfizer Vows Disciplined Financial Allocation; Will Not Chase Price For Buyouts In Markets Like India
WASHINGTON - As the socioeconomic shift gains pace and healthcare is given a higher priority by governments, emerging markets like China, Brazil and India have received heightened attention from global companies looking for deal-making opportunities, but lately, unexpected hurdles have cropped up in the way. "Overly exuberant expectations" may be making future alignments hard, say high level seasoned M&A experts
Novartis, AstraZeneca Pledge Support For Russia At St. Petersburg Economic Forum In Latest Big Pharma Move To Go Local
Russia Premier Vladimir Putin has said he wants multinational pharmaceutical companies to manufacture drugs in Russia and support development of the local industry as part of a $4 billion government initiative to reform the Russia healthcare market by 2020. So perhaps it is not too surprising that both Novartis AG and AstraZeneca PLC chose to re-emphasize their commitments to Russia by each issuing press releases June 16 to coincide with the kickoff of the St. Petersburg International Economic Forum